Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Liabilities and Shareholders Equity (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Liabilities and Shareholders Equity data on record, last reported at $208.8 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 40.49% year-over-year to $208.8 million; the TTM value through Sep 2025 reached $1.0 billion, down 19.29%, while the annual FY2024 figure was $315.3 million, 1.08% up from the prior year.
  • Liabilities and Shareholders Equity reached $208.8 million in Q3 2025 per GOSS's latest filing, down from $240.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $373.4 million in Q2 2024 and bottomed at $181.7 million in Q2 2023.
  • Average Liabilities and Shareholders Equity over 4 years is $281.8 million, with a median of $280.6 million recorded in 2025.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 105.48% in 2024, then crashed 40.49% in 2025.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $272.4 million in 2022, then grew by 14.49% to $311.9 million in 2023, then grew by 1.08% to $315.3 million in 2024, then tumbled by 33.77% to $208.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $208.8 million in Q3 2025, $240.9 million in Q2 2025, and $280.6 million in Q1 2025.